Open Access Open Access  Restricted Access Subscription or Fee Access

Early analgesic effects of intravenous parecoxib and rectal diclofenac following laparoscopic sterilization: A double-blind, double-dummy randomized controlled trial

Alexander Ng, MD, FRCA, Ajay Swami, FFARCSI, Graham Smith, MD, FRCA, Joe Emembolu, FRCOG

Abstract


The aim of this double-blind double-dummy randomized controlled trial was to investigate if there was any difference in analgesia between the maximum recommended doses of rectal diclofenac and iv parecoxib after laparoscopic sterilization. The authors studied 55 ASA I-II patients undergoing gynecological laparoscopy; each patient received either preoperative rectal diclofenac 100 mg and 2 mL of normal saline at induction of anesthesia, or preoperative placebo suppository and 2 mL of parecoxib 40 mg at induction. Pain intensity, sedation, and nausea were measured using a 100-mm visual analogue scale on awakening and at 1, 2, and 3 hour postoperatively. Median (interquartile range) pain intensity at rest on awakening and at 1, 2, and 3 hour postoperatively were 15 (0-40), 37 (10-56), 16 (6-29), and 13 (2-32) mm, respectively, in the parecoxib group, and 3 (0-34), 22 (5-45), 24 (6-37), and 10 (4-21) mm, respectively, in the diclofenac group. There was no significant difference in these scores. Furthermore, there was no significant difference between the two groups in sedation, nausea, rescue analgesia, or rescue antiemetic consumption. Preoperative rectal diclofenac 100 mg and parecoxib 40 mg iv at induction of anesthesia were found to have equianalgesic effects after laparoscopic sterilization. Both drugs appear to be useful after short anaesthetics.

Keywords


analgesics anti-inflammatory, cyclooxygenase- 2 inhibitors; analgesics nonopioid, diclofenac; analgesics nonopioid, parecoxib, randomized trial

Full Text:

PDF

References


Ng A, Habib A, Swami A, et al.: Prospective randomised double-blind placebo controlled clinical trial investigating the effect of transcervical papaverine and bupivacaine on postoperative analgesic requirements following laparoscopic application of Filshie clips. Eur J Anaesthesiol. 2002; 19: 803-807.

Ng A, Parker J, Toogood L, et al.: Does the opioid-sparing effects of rectal diclofenac following total abdominal hysterectomy benefit the patient? Br J Anaesth. 2002; 88: 714-716.

Cheer SM, Goa KL: Parecoxib (parecoxib sodium). Drugs. 2001; 61: 1133-1141.

Ng A, Smith G, Davidson AC: Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth. 2003; 90: 746-749.

DeLoach LJ, Higgins MS, Caplan AB, et al.: The visual analogue scale in the immediate postoperative period: Intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998; 86: 102-106.

Romsing J, Moiniche S: A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for postoperative pain. Acta Anaesthesiol Scand. 2004; 48: 525-546.

Davies NM, Anderson KE: Clinical pharmacokinetics of diclofenac. Clin Pharmacokinet. 1997; 33: 184-213.

Ramakrishna S, Fadnavis NW, Diwan PV: Comparative pharmacokinetic evaluation of compressed suppositories of diclofenac sodium in humans. Arzneim-Forsch/Drug Res. 1996; 46: 175-177.

Ng A, Temple A, Smith G, et al.: Early analgesic effects of parecoxib vs ketorolac following laparoscopic sterilisation: A randomised controlled trial. Br J Anaesth. 2004; 92: 846-849.

Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class Study: A randomised controlled trial. JAMA. 2000; 284: 1247-1255.

Warltier DC, Marret E, Flahault A, et al.: Effects of postoperative, nonsteroidal, anti-inflammatory drugs on bleeding risk after tonsillectomy. Meta-analysis of randomized controlled trials. Anesthesiology. 2003; 98: 1497-1502.

Joshi W, Connelly NR, Reuben SS, et al.: An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003; 97: 35-38.

Juni P, Nartey L, Reichenbach S, et al.: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 2004; 364: 2021-2029.

Bresalier RS, Sandler RS, Quan H, et al.: The adenomatous polyp prevention on Vioxx (APPROVe) cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102.

Gottlieb S: Warnings issued over COX-2 inhibitors in US and UK. BMJ. 2005; 330: 9.

Solomon SD, McMurray JJV, Pfeffer MA, et al.: The adenoma prevention with celecoxib (APC) study. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352: 1071-1080.

Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-1091.

Ott E, Nussmeier NA, Duke PC, et al.: Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003; 125: 1481-1492.

Lloyd K: Important New Safety Information Cardiovascular Risk, Celecoxib, Valdecoxib, Parecoxib. Pfizer 2005 publications.

Ng A, Swanevelder J: Does the opioid-sparing effect of NSAIDs benefit the patient in the postoperative period? J Opioid Manage. 2005; 1: 67-69.




DOI: https://doi.org/10.5055/jom.2008.0008

Refbacks

  • There are currently no refbacks.